"I believe it is risky to not perform intracameral injections," says
Hercules Logothetis, MD, of Cleveland (Ohio) Eye Clinic, which uses
intracameral moxifloxacin. "As long as the surgical center has a reli-
able source of medicine that has been vetted, there should not be
unnecessary concern."
5. Intracamerals could lose their effectiveness. The clock
might be ticking on the effectiveness of intracameral antibiotics. "By
the time the [TIME] study gets done and the drug is on the market,
the resistance is going to be super-high," says Dr. Miller. "We'll use it
as long as it's of some value, but the day is coming when everything
will be resistant to it. And then we'll have to do this super-expensive
$20 million to $30 million study all over again."
Dr. Miller notes that
the use of intracamer-
al antibiotics alone
does not cause resist-
ance, but topical pro-
phylaxis might. "With
topical you get more
resistance, but for
intracameral it's not
possible," he says.
OSM
J U N E 2 0 1 9 • O U T PA T I E N T S U R G E R Y. N E T • 7 3
With increasing regulatory pressure and
the need to reduce costs while improving
the patient experience, access to quality
medicine is more important than ever. ˏˏ
COMPOUNDING HEALTH™ˏ
leiters.com
Your journey to better
medicine begins here.
,$0$()%ˏ%*0.)!.(ˏ%*&!0(!/ˏ%*(1 %*#ˏ
+4%"(+4%*
,$0$()%ˏ .+,/ˏ* ˏ/+(10%+*/
ȥ+),(%*0ˏ.!,'#! ˏ2/0%*ȶˏ
.!ȥ"%((! ˏ/5.%*#!/ˏ* ˏ,%*ˏ/!.2%!/ˏ%*(1 %*#ˏ
,.!ȥ"%((ˏ/!.2%!/ˏ"+.ˏ0$!ˏȥȹˏ%*ˏ!(%!"ˏ
5/0!)
!%0!./ˏ%/ˏˏ0.1/0! ˏȥ.!#%/0!.! ˏȋȅȈˏ
+10/+1.%*#ˏ,.+2% !.ˏ+"ˏ$%#$ȥ-1(%05ˏ
+,$0$()+(+#5ˏ* ˏ$+/,%0(ȥ/! ˏ
)! %0%+*/ˏ* ˏ/!.2%!/ˏ%*(1 %*#Ȓ
2/0%*ȶˏ%/ˏˏ.!#%/0!.! ˏ0. !).'ˏ+"ˏ!*!*0!$ȑˏ *Ȑˏȥȹˏ%/ˏˏ.!#%/0!.! ˏ0. !).'ˏ+"ˏ
2*+/ˏ! %(ȑˏ *Ȑȑˏ+.ˏ%0/ˏ""%(%0!/Ȑˏ ˏȸˏ%/ˏˏ.!#%/0!.! ˏ0. !).'ˏ+"ˏ
!%0!./Ȑˏ
